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Tailoring mTOR-based therapy: molecular evidence 
and clinical challenges
The history of mTOR







; molecular weight: 
914.2), also known as sirolimus, was obtained 
from the bacterium Streptomyces hygroscopicus 
found in soil samples from Rapa Nui (Easter 
Island). In the 1970s, rapamycin was used as 
a potent antifungal agent and shortly after-
wards was found to inhibit cell proliferation 
and possess strong immunosuppressive prop-
erties [1,2]. It took 20 years to identify the 
molecular target of rapamycin and to elucidate 
its mechanism of action. This was achieved by 
selection of spontaneous mutations that con-
fer resistance to the growth inhibitory effect 
of rapamycin in the budding yeast Saccharo-
myces cerevisiae. Three genes were identified. 
The first was RBP1, a homolog of the human 
peptidyl-prolyl isomerase FKBP12, which was 
identified using an FK506 binding column in a 
search for receptors for the immunosuppressant 
drug with structural homology to rapamycin 
[3]. Deletion of RBP1 in yeast resulted in reces-
sive drug resistance while expression of human 
FKBP12 restored rapamycin sensitivity [4]. 
Therefore, rapamycin forms a toxic complex 
with FKBP12 inhibiting the function of other 
cellular proteins [4]. The other two genes were 
TOR1 and TOR2, originally called DRR1 and 
DRR2, which encode two highly homologous 
proteins (~280 kDa) [5,6].
Soon after, mTOR was identified [7]. Unlike 
yeast, higher order eukaryotes have only 
one TOR gene. mTOR is a large (289 kDa) 
serine/threonine protein kinase that belongs to 
the phosphatidylinositol 3 -´kinase-related kinase 
(PIKK) family. At the C-terminus it contains a 
PIKK domain that exhibits serine and threo-
nine kinase activity but not lipid kinase activity 
as seen with the other PIKK family members 
[8]. Another unique characteristic of mTOR, 
which does not exist in the other members of the 
PIKK family, is the 11 kDa FKBP12-rapamycin-
binding domain (FRB) at the N-terminus of the 
PIKK domain [9,10].
Multiprotein complexes of mTOR
Over the last 30 years mTOR-related research 
has provided significant insights into its molecu-
lar architecture and function. Today, it is clear 
that mTOR forms two distinct multiprotein 
complexes: mTORC1 and mTORC2. Both 
complexes are composed of mTOR, mLST8/
GµL, Pras40, Deptor and Tti1/Tel2. Raptor and 
Pras40 are specific to mTORC1, while Rictor, 
Protor 1/2 and mSin1 are specific to mTORC2 
(Box 1) [11].
In response to growth factors, stress, amino 
acids and oxygen, mTORC1 regulates numerous 
pathways including cell growth, autophagy, pro-
tein synthesis, cell cycle and metabolism. The 
best-known mTORC1 substrates are S6K1 and 
4E-BP1, both of which are involved in the regu-
lation of protein synthesis. Importantly, S6K1 
was shown to form a negative feedback loop 
by inhibiting expression of the insulin receptor 
substrate, attenuating the PI3K/Akt pathway 
(Figure 1) [12,13].
The mTOR signaling pathway integrates inputs from a variety of upstream stimuli to regulate diverse 
cellular processes including proliferation, growth, survival, motility, autophagy, protein synthesis and 
metabolism. The mTOR pathway is dysregulated in a number of human pathologies including cancer, 
diabetes, obesity, autoimmune disorders, neurological disease and aging. Ongoing clinical trials testing 
mTOR-targeted treatments number in the hundreds and underscore its therapeutic potential. To date 
mTOR inhibitors are clinically approved to prevent organ rejection, to inhibit restenosis after angioplasty, 
and to treat several advanced cancers. In this review we discuss the continuously evolving field of mTOR 
pharmacogenomics, as well as highlight the emerging efforts in identifying diagnostic and prognostic 
markers, including miRNAs, in order to assess successful therapeutic responses.
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In contrast to mTORC1, little was known 
about mTORC2 until an important discovery 
demonstrated that mTORC2 is able to regulate 
cell proliferation, survival and metabolism by 
phosphorylating Akt on a key activation site 
(Ser473) [14,15]. Notably, Akt activates mTORC1 
by phosphorylating and inhibiting the tuber-
ous sclerosis complex, which negatively regu-
lates mTORC1 by inhibiting the small GTPase 
Rheb that in turn directly activates mTORC1 
(Figure 1) [16].
Dysregulation of the mTOR pathway has 
been linked to several pathological conditions, 
including cancer, diabetes, obesity, autoimmune 
disorders, neurological disease and aging, mak-
ing it an attractive target for the development of 
new pharmacological treatments [11,17,18].
Rapamycin: mechanism of action 
& first applications
Upon entering the cell, rapamycin binds to 
FKBP12, which then interacts with the FRB 
domain of mTORC1 inhibiting its serine/threo-
nine kinase activity and preventing the transla-
tion of specific cell cycle mRNAs required for 
G1 to S phase transition, ultimately leading to 
growth arrest [19,20]. By contrast, the rapamy-
cin–FKBP12 complex cannot interact with the 
FRB domain of mTORC2, and therefore cannot 
inhibit it acutely. In some cases, chronic treat-
ment with rapamycin has been shown to block 
the mTORC2 assembly, thereby inhibiting its 
activity [21].
In 1999, rapamycin was approved by the 
US FDA as an immune suppressor agent to 
prevent organ rejection in renal transplant 
patients. Shortly thereafter, a number of studies 
demonstrated that rapamycin was also a potent 
inhibitor of vascular smooth muscle prolifera-
tion and migration [19,22–24]. These findings led 
to the development of the rapamycin-eluting 
stent used to treat atherosclerotic blockages in 
coronary arteries, which was approved by the 
FDA in 2003 to prevent in-stent restenosis. The 
antiproliferative properties of rapamycin were 
also tested in a broad range of malignancies and 
numerous clinical trials have been conducted.
n First-generation inhibitors of mTOR
After the discovery of rapamycin and the elu-
cidation of its mechanism of action, other 
macrolide ester derivatives (also known as 
‘rapalogs’) that share the same mechanisms of 
action have been synthesized both to improve 
pharmaco kinetic properties and to ensure patent 
protection (Figure 2). These include everolimus 
(RAD001) marketed by Novartis; temsiroli-
mus (CCI-779) developed by Wyeth Pharma-
ceuticals; and deforolimus or ridaforolimus 
(AP23573) codeveloped by Merck and ARIAD 
Pharmaceuticals.
Everolimus (RAD001)
Everolimus is an oral rapamycin analog (half-
life: 30 h). It was approved by the FDA for the 
treatment of patients with advanced kidney 
cancer [25]; for the treatment of subependy-
mal giant cell astrocytoma, alone or associated 
with tuberous sclerosis complex [26–28]; for pro-
gressive neuroendocrine tumors of pancreatic 
origin in patients with tumors not surgically 
removable; and for advanced hormone recep-
tor-positive, HER2-negative breast cancer in 
combination with exemestane, after failure 
of treatment with anastrozole or letrozole [29]. 
Recently, the addition of everolimus to trastu-
zumab and vinorelbine was shown to extend 
progression-free survival in women with HER2-
positive advanced breast cancer, compared with 
treatment with placebo plus trastuzumab and 
vinorelbine, in the Phase III BOLERO-3 trial. 
The study enrolled women whose disease was 
resistant to prior trastuzumab treatment (Data 
presented at American Society of Clinical 
Oncology [ASCO] Meeting, June 2013 [30]). 
Everolimus is also used for the prevention of 
organ rejection after renal or heart transplants 
and in drug eluting coronary stents (Xience). 
The drug is being tested as a therapy for pros-
tate, colorectal and non-small-cell lung cancers 
as either a single agent or in combination with 
additional therapies.
Temsirolimus (CCI-779)
Temsirolimus is a water-soluble ester derivative 
of rapamycin available in oral and intravenous 
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formulations (half-life: 13–22 h). In 2007, it 
was approved by the FDA for the treatment of 
advanced-stage renal cell carcinoma [31]. It rep-
resents the first mTOR inhibitor approved for 
cancer therapy. Temsirolimus was also approved 
in Europe for the treatment of mantle cell lym-
phoma [32]. Temsirolimus is currently being 
tested either alone or in combination therapy 
in tumor types such as melanoma, myeloma, 
and renal and gynecological cancers.
Deforolimus or ridaforolimus (AP23573)
Ridaforolimus is an oral rapamycin analog (half-
life: 56–74 h) that selectively targets mTOR and 
has been shown to possess potent anti tumor 
activity both in cell lines and in xenograft tumor 
models. It is currently being evaluated (Phase III) 
in non-small-cell lung cancer, glioblastoma, soft 
tissue and bone sarcoma, prostate, endometrial 
and pancreatic cancer, metastastic breast cancer 
and relapsed hematological tumors. It has thus 
far shown good tolerability with dose-limiting 
stomatitis in both single and combination treat-
ments. In November 2012, Merck officially with-
drew its application for a marketing authoriza-
tion for deforolimus concerning the maintenance 
treatment of patients with metastatic soft tissue 
sarcoma or bone sarcoma previously treated with 
chemotherapy owing to inconclusive benefit–risk 
balance evaluations.
Clinical challenges
Rapalogs are generally well-tolerated and do 
not lead to changes in blood pressure, liver 
function or renal toxicity, although fatigue, 
rash, hematological abnormalities and gas-
trointestinal disturbances are quite com-
mon. In addition, hypercholesterolemia and 
hyper triglyceridemia have also been reported; 
therefore, the monitoring of blood lipid levels 
is  recommended [33].
The mTOR-targeted therapies are currently 
being evaluated in 1444 clinical trials (clinical-
trials.gov [101]) as single agent or in combina-
tion therapies. In preclinical studies performed 
in vitro and in vivo they have shown significant 
antiproliferative activity against a broad panel 
of tumors, with encouraging safety profiles and 
clinical benefit responses, achieving disease 
stabilization and/or tumor regression owing to 
inhibition of tumor cell proliferation. Notably, 
inhibition of the mTOR pathway also exerts 
antiangiogenic effects, mainly attributable to 
the fact that mTOR controls the production 
of HIF1a, which in turn mediates the expres-
sion of several angiogenic genes [34]. However, 
despite the proven efficacy of rapalogs against 
a number of tumors, their anticancer activity is 
quite unpredictable [35].
The negative feedback loop that exists down-







































Figure 1. mTOR signaling pathways.  
GF: Growth factor; GFR: Growth factor receptor; TSC: Tuberous sclerosis complex.
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observed resistance to rapalogs. Since active 
mTORC1 suppresses the PI3K/Akt pathway, 
mTORC1 inhibition by rapalogs abolishes the 
negative feedback loop, resulting in hyper-
activation of the PI3K/Akt signaling and 
leading to increased cell survival (Figure 1) [36]. 
Notably, rapamycin-insensitive functions of 
mTORC1 were recently revealed, challenging 
the dogma that rapamycin completely inhibits 
mTORC1 activity [37,38]. Alternative survival 
pathways and crosstalk with other signaling 
pathways including MEK/ERK could also 
limit the efficacy of rapalogs [39]. In human 
cancers, inhibition of mTORC1 leads to MAPK 
pathway activation through a PI3K-dependent 
feedback loop [40]. Indeed, the combination of 
temsirolimus with the MAPK inhibitor, SL327, 
significantly reduced brain metastases in vivo, 
while treatment with temsirolimus alone yielded 
no significant effect [41].
n Second-generation inhibitors 
of mTOR
New drugs, referred to as mTOR kinase domain 
inhibitors, are being developed to inhibit 
the ATP binding site of both mTORC1 and 
mTORC2. These drugs are small molecules 
that bind competitively and reversibly to the 
mTOR–ATP binding pocket, blocking the 
enzymatic activity of the kinase. Numerous 
mTORC1 and mTORC2 inhibitors are under 
preclinical evaluation and in Phase I/II clini-
cal trials for various cancers (TaBle 1). Although 
mTOR kinase inhibitors target both complexes, 
preclinical and early clinical data showed hyper-
activation of the PI3K/Akt signaling caused by 
decreased mTORC1 activity, which superseded 
the effects of inhibition of mTORC2.
Since the catalytic domain of mTOR and the 
p110a subunit of PI3K are highly homologous, 


































































Figure 2. Molecular structures of rapamycin and the first generation of mTOR inhibitors 
(rapalogs).
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activity against both PI3K and mTOR [42]. The 
main advantage of such dual inhibitors is the 
simultaneous inhibition of PI3K–Akt–mTOR 
signaling and reduction of the hyperactivation 
of PI3K that typically results in mTORC1 inhi-
bition. Numerous dual PI3K/mTOR inhibitors 
have already entered Phase I and II clinical trials 
for a variety of cancer types, either alone or in 
combination with other chemotherapies (TaBle 1). 
Early clinical results suggest that these dual 
PI3K/mTOR inhibitors are more efficacious 
than rapalogs, but also demonstrate increased 
toxicity. This was especially evident in the diges-
tive tract with adverse effects including diarrhea, 
nausea and vomiting. Hyperglycemia has also 
been reported.
Molecular biomarkers for  
mTOR-targeted therapy
Our knowledge of the mTOR pathway has 
increased dramatically in recent years, yet 
many gaps still exist in our understanding of the 
molecular mechanisms involved in the response 
of cancer cells to such inhibitors. Therefore, 
there is an urgent need for efficient biomark-
ers not only to predict who will benefit from 
mTOR-targeted therapies, but also for patients 
to avoid developing unnecessary toxicities. In 
recent years, determinants of rapalog sensitiv-
ity and resistance have begun to emerge [43]. 
Several preclinical and clinical models showed 
that cancer cells where the mTOR pathway is 
hyperactive owing to PTEN deficiency [44], 
Akt phosphorylation [45] or PI3K mutations 
[39] are particularly sensitive to mTOR inhibi-
tors. Tumor cells that have functional apoptotic 
pathways, overexpress cyclin D1 [32,46], or have 
greatly increased angiogenic signaling [47] are 
more sensitive to rapamycin. Overexpression 
of antiapoptotic proteins such as Bcl2 may also 
serve as viable predictors of resistance to mTOR 
inhibitors [48]. Recently, we showed that rapamy-
cin treatment was effective primarily in tumors 
that exhibit rapamycin-sensitive dephosphoryla-
tion of Akt and consequently decreased expres-
sion of the oncogene Skp2 [49]. However, these 
and many others candidate biomarkers still need 
to be validated in the clinical setting.
miRNAs & mTOR
miRNAs are small ncRNAs (22 nucleotides) 
that regulate gene expression at the post- 
transcriptional level by either translational 
repression or mRNA cleavage [50]. miRNAs 
play an essential role in tumorigenesis, and it has 
recently been shown that circulating miRNAs 
can be measured in the serum and are emerging 
as a novel class of biomarkers for both diagnostic 
and prognostic assessments, giving rise to the 
field of miRNA pharmacogenomics [51,52].
Recently, various studies showed that miRNAs 
affect the mTOR pathway by targeting upstream 
regulators including IGF-R, PI3K, PTEN and 
Akt. Here we will focus on the functional role 
of miRNAs in the cellular response to mTOR 
inhibitors and the reciprocal regulation of mTOR 
Table 1. Second-generation mTOR and PI3K inhibitors currently in clinical trials 
according to clinicaltrials.gov.
Inhibitor Targets Status Tumor Ref.
OSI-027 mTORC1/mTORC2 Phase I Solid tumors [74,75]
Palomid 529 mTORC1/mTORC2 Phase I Macular degeneration [76]
AZD8055 mTORC1/mTORC2 Phase I Multiple cancers [77–80]
INK 128 mTORC1/mTORC2 Phase I Solid tumors [81]
AZD2014 mTORC1/mTORC2 Phase I Solid tumors [82]
CC-223 mTORC1/mTORC2 Phase I Solid tumors
CC-115 mTORC1/mTORC2 Phase I Solid tumors
GSK1059615 PI3K/mTORC1/mTORC2 Phase I Multiple cancers [83]
PF-05212384 (PKI-587) PI3K/mTORC1/mTORC2 Phase I Solid tumors [84]
XL765 (SAR245409) PI3K/mTORC1/mTORC2 Phase I Solid tumors [85]
PF-04691502 PI3K/mTORC1/mTORC2 Phase I Solid tumors [86]
DS-7423 PI3K/mTORC1/mTORC2 Phase I Solid tumors
NVP-BEZ235 PI3K/mTORC1/mTORC2 Phase I/II Multiple cancers [87–90]
GDC-0980 PI3K/mTORC1/mTORC2 Phase I/II Multiple cancers [91]
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and miRNAs (Figure 3). We demonstrated that 
rapamycin-resistant myogenic cells, developed 
by prolonged rapamycin treatment, displayed an 
extensive reprogramming of the miRNA tran-
scriptome, characterized by upregulation of the 
oncogenic miR-17–92 and related clusters and 
downregulation of tumor suppressor miRNAs, 
such as miR-143, miR-29 and miR-22. Con-
versely, rapamycin-sensitive cells exhibited an 
increase in tumor suppressor miRNAs. Intrigu-
ingly, inhibition of members of the miR-17–92 
cluster or delivery of tumor suppressor miRNAs 
restored sensitivity to rapamycin [53,54]. In sup-
port of our findings, rapamycin was shown to 
increase expression of miR-143 in human glioma 
cells [55]. Additionally, everolimus increased 
miR-143 expression in a time-dependent manner 
in human pancreatic cancer cells [56]. Endothelial 
cells treated with rapamycin showed increased lev-
els of miR-21, mediating the antiproliferative and 
antimigration effect of rapamycin [57]. Moreover, 
mTOR was shown to control MyoD-dependent 
transcription of miR-1 in differentiating myo-
blasts and in mouse regenerating skeletal muscle 
[58]. Another report demonstrated that mTOR, by 
negatively controlling miR-125b biogenesis, regu-
lates the production of IGF-II, a master switch 
governing the initiation of skeletal myogenesis [59].
On the other hand, several miRNAs, includ-
ing miR-7a and miR-99a, were shown to directly 
target different components of the mTOR 
pathway [60–63]. Inhibition of miR-7a activated 
mTOR signaling and promoted adult b-cell rep-
lication in primary islets, which was reversed by 
rapamycin treatment [63]. In oral squamous cell 
carcinoma and renal cell carcinoma, miR-99a 
was shown to directly modulate mTOR signaling 
pathways [61,62]. miR-99a downregulation was 
also associated with mTOR upregulation in vari-
ous human lung cancer cells/tissues [64]. Inter-
estingly, downregulation of miR-99a has been 
detected in different human cancers in which 
tumor growth was mediated by the upregulation 
of the tyrosine kinase c-Src [64]. Re-expression 
of miR-99a suppressed tumor growth of c-Src-
transformed cells, and this effect was restored 
by mTOR overexpression. Down regulation of 
miR-99a was also observed in EGF- and Ras-
transformed cells, and was suppressed by inhib-
iting the MAPK pathway [64]. Additionally, in 
colorectal cancer, miR-144 downregulation led 
to poor prognosis via activation of the mTOR 
signaling pathway [65]. In oral squamous cell 
carcinoma, miR-218 targeted Rictor lead to an 
inhibition of Akt phosphorylation at Ser473 [66]. 
miR-100 was shown to repress mTOR signal-
ing in endothelial and vascular smooth muscle 
cells, displaying an antiangiogenic function. 
Whereas miR-100 inhibition increased mTOR 
levels in endothelial cells, overexpression of 
miR-100 reduced mTOR expression and conse-
quently attenuated cellular proliferation [67]. In 
clear-cell ovarian carcinoma cell lines, mTOR 
was repressed by miR-100 at the mRNA and 
protein levels, and decreased phosphorylation 
of 4EBP1 and p70 S6 kinase were also observed 
[68]. Human cytomegalovirus infection altered 
the expression of miR-100 and miR-101 to target 
components of the mTOR pathway, resulting in 
an improved ability to replicate [69]. In childhood 
adrenocortical tumors, miR-99a and miR-100 
coordinately regulated the expression of mTOR, 
Raptor, and IGF via binding sites in their 
3 -´UTR regions [70]. In esophageal squamous 
cell carcinoma, wherein decreases in miR-99a 
and miR-100 are correlated with worse overall 
survival, miR-99a and miR-100 suppressed the 
expression of mTOR by directly binding to its 
3 -´UTR [71]. miR-101 was also shown to target 
mTOR in anaplastic large-cell lymphoma [72]. In 
a different study, miR-199a-3p, which is known 
to be downregulated in several human malig-
nancies and in hepatocellular carcinoma, was 
also shown to target mTOR. The inhibition of 
miR-199a-3p in hepatocellular carcinoma cells 
led to G(1)-phase cell cycle arrest [73].
Future perspective
Our knowledge about the mTOR pathways 
has seen extraordinary advances over the past 















Figure 3. Model of the reciprocal regulation of mTOR and miRNAs.
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the vastly versatile roles this molecule plays in 
cellular processes makes it enormously signifi-
cant in human physiology and pathophysiol-
ogy. Despite the challenges, mTOR-targeted 
therapies remain very attractive and promising. 
It is necessary to design future clinical trials 
to include validation of potential biomarkers. 
Research focusing on this particular area of 
investigation will certainly produce a plethora 
of invaluable information with regards to mTOR 
pharmacogenetics and pharmacogenomics, con-
tributing to the advancement of drug discovery 
for the treatment of various human disorders in 
which the mTOR signaling pathway is involved. 
Eventually, novel therapeutic targets are likely to 
emerge downstream of mTOR with less toxicity, 
improved specificity and greater clinical benefits. 
Recent evidence describing how miRNAs regu-
late mTOR pathways will provide the framework 
for their development as diagnostic and prognos-
tic biomarkers as well as for the design of novel 
therapeutic tools in the clinic.
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  Rapamycin is a bacterial product (Streptomyces hygroscopicus) found in soil samples from Rapa Nui (Easter Island).
  The first targets of rapamycin (Tor1, Tor2 and FKBP12) were identified in Saccharomyces cerevisiae.
  Eukaryotes have only one TOR gene, which is called mTOR.
Multiprotein complexes of mTOR
  mTOR forms two distinct multiprotein complexes: mTORC1 and mTORC2.
  The mTOR pathway has been linked to several disorders including cancer, diabetes, obesity, autoimmune disorders, neurological disease 
and aging.
Inhibitors of mTOR
  Rapamycin (sirolimus) is a natural compound that has been approved in the clinical scenario as an immunosuppressant in  
kidney-transplanted patients and as an antiproliferative agent to prevent in-stent restenosis after angioplasty.
  The first-generation inhibitors of mTOR are analogs of rapamycin, also known as rapalogs, and include temsirolimus, everolimus and 
deforolimus.
  The second-generation inhibitors of mTOR are comprised of new compounds able to inhibit the ATP-binding site of mTORC1 and 
mTORC2, or PI3K and both mTORC1 and mTORC2.
Molecular biomarkers in mTOR-targeted therapy
  Numerous gaps still exist in our understanding of the molecular mechanisms underlying the response to mTOR inhibitors.
  There is an urgent need for efficient biomarkers not only to predict who will benefit from mTOR-based therapy but also to avoid the 
development of unnecessary toxicity.
miRNAs & mTOR
  miRNAs have been recently identified as new regulators of the mTOR-signaling pathway.
  miRNAs play a functional role in the response to mTOR inhibitors.
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